Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2000
A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expressionJ V Falvo, B M Brinkman, A V Tsytsykova, et al.Leukemia|December 21, 2011
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibE Weisberg, A K Azab, P W Manley, et al.Leukemia|September 14, 2007
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessmentM C Stubbs, Y M Kim, A V Krivtsov, et al.Molecular Cell|November 11, 1998
p300/MDM2 complexes participate in MDM2-mediated p53 degradationS R Grossman, M Perez, A L Kung, et al.The Journal of Biological Chemistry|April 11, 2001
A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrixW T Tse, J Tang, O Jin, et al.Leukemia|August 24, 2011
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityM M Reddy, M S Fernandes, A Deshpande, et al.Science (New York, N.Y.)|June 9, 2001
Role of T-bet in commitment of TH1 cells before IL-12-dependent selectionA C Mullen, F A High, A S Hutchins, et al.Leukemia|December 14, 2012
Cell of origin determines clinically relevant subtypes of MLL-rearranged AMLA V Krivtsov, M E Figueroa, A U Sinha, et al.Leukemia|September 17, 2010
Smac mimetics: implications for enhancement of targeted therapies in leukemiaE Weisberg, A Ray, R Barrett, et al.Leukemia|April 4, 2012
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitorsE Weisberg, Q Liu, Erik Nelson, et al.Pageof 3